A model for the 3D structure of the transmembrane domain of the 6 opioid receptor was predicted from the sequence divergence analysis of 42 sequences of G-protein coupled peptide hormone receptors belonging to the opioid, somatostatin and angiotensin receptor families. No template was used in the prediction steps, which include multiple sequence alignment, calculation of a variability profile of the aligned sequences, use of the variability profile to identify the boundaries of transmembrane regions, prediction of their secondary structure, optimization of the packing shape in a helix bundle, prediction of side chain conformations and structural refinement The general shape of the model is similar to that of the low resolution rhodopsin structure in that the TM3 and TM7 helices are most buried in the bundle and the TM1 and TM4 helices are most exposed to the lipid phase. An initial assessment of this model was made by determining to what extent a binding site identified using four structurally disparate high affinity 8 opioid ligands was consistent with known mutational studies. With the assumption that the protonated amine nitrogen, a feature common to all 5 opioid ligands, interacts with the highly conserved Aspl27 in TM3, a pocket was found that satisfied the criteria of complementarity to the requirements for receptor recognition for these four diverse ligands, two 5 selective antagonists (the fused ring naltrindole and the peptide Tyr-Tic-PhePhe-NH 2 ) and the two agonists lofentanil and BW373U86 deduced from previous studies of the ligands alone. These ligands could be accommodated in a similar region of the receptor. The receptor binding site identified in the optimized complexes contained many residues in positions known to affect ligand binding in G-protein coupled receptors. These results also allowed identification of key residues as candidates for point mutations for further assessment and refinement of this model as well as preliminary indications of the requirements for recognition of this receptor.
Introduction
The observation of antinociceptive activity for opioid narcotics has a long history. Before the endogenous peptide opioids were discovered (Hughes etal., 1975) , many structurally diverse families related to morphine were synthesized and evaluated for this activity (Casy and Parfitt, 1986) . After the discovery of the enkephalins, one family of endogenous opioid peptides, structure-activity relationships (SARs) studies of opiates were expanded to include extensive synthesis and evaluation of new opioid peptides, as well as a continued search for novel non-peptide compounds. These combined efforts resulted in a vast SAR database which over the years has served as a basis for a number of studies focusing on pharmacophore development i.e. identification of molecular determinants of recognition and activation of opioid receptors. Lacking structures of the receptors, these efforts necessarily focused on characterizing and comparing the properties of the ligands themselves, using the techniques of computational chemistry. These studies have provided insights into the requirements for recognition and activation initially for a single and subsequently for multiple opioid receptors, as pharmacological evidence for receptor subtypes was reported (Jaffe and Martin, 1990) . They included the characterization of both peptides and non-peptides (Beckett and Casy, 1954; Gait, 1977; Loew and Burt, 1977; Gorin etal., 1980; Loew etal., 1982; Perez etal., 1992; Portoghese, 1992) and more recently, efforts to define pharmacophores for each receptor subtype that could be useful in the design of receptor selective ligands (Cometta-Morini and Loew, 1991, 1992; ComettaMorini etal, 1992; Perez and Loew, 1993) .
The opioid receptors belong to the superfamily of G-protein coupled receptors (GPCRs). These are integral membrane proteins presumed to have the common structural motif of seven transmembrane (TM) helices (Bockaert, 1991; Hargrave, 1991) . All subtypes of opioid receptors thus far characterized are coupled to G, proteins and lead to inhibition of the formation of cyclic AMP (Herz, 1993) . While the sequences of many other G-protein coupled neurotransmitter and peptide hormone receptors have been known for ten years or more, it is only very recently that definitive evidence for multiple opioid receptor subtypes was obtained by the use of the techniques of recombinant DNA to clone and sequence the three major subtypes, specifically mouse and rat 8 (Evans etal., 1992; Kieffer etal., 1992; Yasuda etal., 1993) , mouse and rat K (Meng and Akil, 1993; Yasuda etal., 1993) and rat and human u. (Chen etal., 1993; Wang etal., 1994) opioid receptors.
While knowledge of the sequences of the opioid receptors represents a tremendous advance, sequences alone are not enough to identify key regions of the receptor responsible for ligand binding and function. Very useful information in this regard can be obtained from studies of the effect of mutations on ligand binding and receptor activation. Such studies are just emerging for the newly characterized opioid receptors (Kong and Reisine, 1993; Surratt et ai, 1994) . However, given the large number of amino acids in these receptors, some criteria that can be a useful guide to choice of candidate residues for mutation are essential. Lacking any three-dimensional (3D) structures of GPCRs, models of the 3D structures obtained by diverse computational strategies can be very useful in this regard, and also in providing initial insights into ligandreceptor interactions and function.
Models of the 3D structures of the TM regions of many GPCRs have been built by homology modeling (Dahl etal, 1991; Grotzinger etal, 1991; Hibert etal, 1991; Livingstone etal, 1992; Maloney-Huss and Lybrand, 1992; TrumppKallmeyer etal, 1992; Ward and Sauerberg, 1992; Cronet etal, 1993; Nordvall and Hacksell, 1993; Yamamoto etal, 1993) using the low resolution structure of bacteriorhodopsin (BR), a membrane protein (Henderson etal, 1990) , as a template. However, the extremely low sequence homology between the sequences of most GPCRs and BR (=£10%) implies that the structures of GPCRs may not be the same as that of BR. Indeed, a low resolution density map of bovine rhodopsin, a member of the GPCR family, shows clear differences in the packing shape of the TM helices as compared with that of BR (Schertler etal, 1993) . Therefore, alternative strategies for constructing models of GPCRs, that do not involve use of BR as a template, are also being actively explored (Baldwin, 1993; Smolyar and Osman, 1993; Zhang andWeinstein, 1993; Perlmanef al, 1994; Zhou et al, 1994) . A recent review describes and compares the different procedures being used in this active field (Ballesteros and Weinstein, 1994) .
Among these alternative strategies, the particular approach developed in our group is based on sequence divergence for the prediction of the seven TM helical domains of integral membrane proteins. We have applied it to the construction of models of BR (Du and Alkorta, 1994) and human rhodopsin (Alkorta and Du, 1994 ). The 3D model of BR built using this method agrees with the general features of its experimental structure (Du and Alkorta, 1994 ). The 3D model for human rhodopsin (Alkorta and Du, 1994) , a member of the opsin family of GPCRs, was found to be consistent with the low resolution electron density map of bovine rhodopsin (Schertler, 1993) and the key residues in direct interaction with the retinal chromophore determined by experiments.
The aim of the present work was to construct a 3D model of the 5 opioid receptor using the same method of sequence divergence analysis as in the two previous studies together with the sequences currently available for peptide hormone receptors, one of the major subfamilies of the GPCR superfamily. This method does not include helix tilt and uses ideal helix geometry to construct an initial 3D model of the TM domain. Since trie detailed placement of the ligand in the binding pocket can be affected by these limitations, the validity of the optimized model was assessed by the extent to which a candidate binding site identified using four structurally diverse, high 8 affinity ligands contained many residues in positions known to affect ligand binding in GPCRs. These results also allowed identification of key residues as candidates for point mutations for future assessment and refinement of this initial model, as well as preliminary indications of the requirements for recognition of this receptor.
Materials and methods

Construction of a 3D model of the receptor
The method of sequence divergence analysis used to construct a 3D model of the transmembrane domain of the mouse 5 opioid receptor is described in detail elsewhere (Du and Alkorta, 1994) , including comparisons of the key steps used with other methods. The steps that were used are summarized below.
(i) Sequences with >20% sequence homology with the opioid receptor were selected for inclusion in the analysis. IC5o is the concentration of compound that causes 50% inhibition of electrically stimulated contraction in mouse vas deferens in the presence of B-FNA to mask \l receptors in this tissue. "References: 1, Maguire and Loew, 1993; 2, Chang etal., 1993; 3, Maguire etal., 1992; 4, Schiller and Chung, 1992 . c Naltrindole shows no activity at concentrations up to I mM. Although there are more than one hundred known sequences of peptide receptors, only two peptide hormone receptor families, namely angiotensin and somatostatin, satisfied this requirement, leading to a total of 42 peptide receptor sequences being included in this study.
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(ii) Multiple sequence alignment was performed. The peptide sequences were aligned using the program CLUSTALV (Higgins etal, 1992 ) using a fixed gap penalty of 20. Minor visual adjustments were carried out for a. few insertion regions to remove unnecessary gaps.
(iii) The amino acid variability index, V ; , was calculated at every residue position in the consensus alignment. In previous studies of the pattern of amino acid substitutions (Komiya etal, 1988; Rees etal, 1989a,b; Overington etal, 1990; Donnelly etal, 1993) , substitutions between all pairs of sequences were treated equally. However, it is important to incorporate the homology of the sequences in the calculation of amino acid variability, since mutations between sequences of higher homology are more accurate predictions of residue accessibility (Go and Miyazawa, 1980; Benner and Gerloff, 1991) . In this study the definition of the variability index was modified in two ways as compared with previous ones reported. First, multiple percent cut-off values (e.g. 80%, 70%, etc.) were used. At each cut-off value chosen, only variations within subfamilies with minimal percent identities equal to or larger than this cut-off were considered. Second, variations involving hydrophilic and lipophilic residues were separately calculated as a hydrophilic and a lipophilic variability index respectively. Briefly, four assumptions were used in the calculation of the variability index at each alignment position: (i) solventaccessible residues are those involved in frequent mutations of hydrophilic residues; (ii) lipid-accessible residues are those involved in frequent mutations between lipophilic residues; (iii) variations observed between sequences of higher homology are more reliable indications of both types of surface residues than variations observed between sequences of lower homology; (iv) at a given percent identity cut-off, variations observed in several subfamilies are more reliable indications of accessible residues than variations found in only one subfamily. Using these assumptions, a weighted variability index, V(y), at alignment position_/' was calculated by dividing the sequences into different sets of subfamilies corresponding to multiple percent identity cut-off values and using the following relationships:
and V H (J) is hydrophilic variability, TM1  TM2  TM3  TM4  TM5  TM6  TM7   Lofentanil   TM1  TM2  TM3  TM4  TM5  TM6  TM7   BW37U86  TMI  TM2  TM3  TM4  TM5  TM6  TM7 Tyr-Tic-Phe- Phe-NH 2  TMI  TM2  TM3  TM4  TM5  TM6  TM7 Y55 ( 
V..f n -V
Reference Krystek and Webb, 1994 Rao etal., 1994 Strader et al.. 1989 Fraser et al., 1989 Mansour et al., 1992 Fraser et al., 1989 Tomic et al., 1993 Tomic etal., 1993 Green etal., 1993 Fong etal., 1993 Yamano etal., 1992 Pollocks al., 1992 Strader etal., 1989 Fong etal., 1993 Woodward etal., 1994 Oksenberg and Ashkenazi. 1992 Townsend-Nicholson et al., 1994 ; sub H (jk)
N. cut t •= 1 suHjk)
and N ml is the total number of different values of percent identities used. In this study, N cal = 7 since seven different percent identity cut-offs (from 30 to 90% in 10% increments) were used. At each cut-off value used, the number of subfamilies with lipophilic mutations, sub L (Jk) of hydrophilic mutations, sub H (Jk) is normalized by dividing by the total number of subfamilies, sub{k). A subfamily is considered to have a lipophilic mutation at an alignment position if only lipophilic (A, V, L, I, M, F, Y and W) or neutral (G, P, S, T and C) residues are found at this position and at least one mutation exists between these residues. A subfamily is considered to have a hydrophilic mutation at an alignment position if there is at least one mutation from a hydrophilic residue (D, E, K, R, N, Q or H) or a deletion to any other type of residue or deletions as well as mutations between neutral residues.
(iv) The TM regions were identified. Regions with contigu- Table IV. ous non-negative V(J) values were identified as TM segments. The TM boundaries were defined at the transition points between the positive V(J) values inside the TM region and the negative V(J) values in the adjacent solvent-exposed region.
(v) The secondary structure of the TM regions was predicted using the periodicity of V(j), according to the Fourier transform power spectrum, P(co) (Cornette and DeLisi, 1987) and the alpha periodicity index, AP (Donnelly etal,, 1993) . After verification of helical conformations for the TM regions, a model of each individual helix of mouse 8 opioid receptor w?s constructed with standard <t>/iy angles for the backbone and extended side chains using QUANTA/CHARMM (Brooks etal., 1983) .
(vi) The TM helices were packed into a 3D model. The following assumptions were used in constructing the 3D model. Firstly, the TM helices form a closed bundle, as they do in both BR (Henderson etal, 1990) and rhodopsin (Schertler etal, 1993) . Secondly, the helices are packed in a sequential order, based on the fact that a short connecting loop can always be found between the TM helices for some members of the GPCR superfamily (Zhou et al, 1994) . Thirdly, helices are packed in an antiparallel fashion except for helices 1 and 7, which are parallel. Helix tilt is not included in this model. Lastly, ideal helical geometries were used to construct the initial model. This assumption does not include the effect of kinks, which have been systematically investigated in other strategies (Ballesteros and Weinstein, 1994 ).
The variability profile was then used to predict two important features of the 3D model of the 5 opioid receptor, namely the packing shape of the bundle and the orientations of the helices inside the membrane.
The packing shape of the helix bundle was predicted using the average variability, <V>, of each helix, in three steps.
Firstly an optimum 2D model was predicted. In the procedure used, the TM helices were reduced to two-dimensional rings of 10.5 A diameter (Figure 1 ). The internal angles formed by the centers of three adjacent rings, 9, were varied iteratively with an initial increment of 10° between 60 and 300°. Each set of values of these internal angles, corresponding to a bundle shape, was assessed for the extent to which the average variability of each helix was proportional to the exposed arc length, /, of each ring taken as an indication of its lipid accessibility. The resulting bundle that gave the best linear correlation between <V> and the exposed arc length for each ring was used in the next round of grid search with a smaller increment and narrower ranges of 8. The final 2D structure chosen was the one with the highest correlation coefficient using an increment of 1 ° in the angle 8.
In step two, the optimal 2D model was used to construct a 3D model by placing the seven TM helices in the positions of the rings antiparallel to each other, except for the first and last helices which were made parallel. The helix orientations were predicted by calculating the variability moment VM using the equation VM= t-v. where s, is a unit vector from the C a atom to the opposite of the vector bisecting the C a -C and C a -N bonds of residue j in the model structure of this TM region. Each helix was then oriented with this vector pointing towards the lipid phase. The initial 3D model was then improved by slight rotations of the helices so that residues known to affect ligand binding (Fraser et al, 1989; Strader et al, 1989a,b; Nathans, 1990; Neitz et al, 1991; Wess et al, 1991; Oksenberg et al, 1992; Pollock et al, 1992; Ridge etal, 1992 1993 ; Funk etal, 1993; Green etai, 1993; Shenker etai, 1993; Smolyar and Osman, 1993; Tomic etai, 1993; Krystek and Webb, 1994; Rao etal, 1994; Townsend-Nicholson and Schofield, 1994; Woodward etal, 1994) were placed inside the helix bundle. In step three, for each candidate 3D model, the lipid accessibility. A, of each residue was calculated. The criterion used to assess each 3D model was the extent to which the average lipid accessibility of all residues in each helix was proportional to its average variability. The accessibility of residue X was calculated as the ratio of the lipid-accessible area of this residue in the model over the accessible area of this residue in an extended conformation in the tripeptide GXG. The Connolly algorithm (Connolly, 1983) was used for the calculation of the lipid-accessible area with a probe of 2.0 A and a surface dot density of 10 A 2 . From these individual values of accessibility, an average value, <A>, was calculated for each helix and plotted against <V>. Manual adjustment of the positions of the TM helices was carried out to improve this correlation, until the correlation coefficient (r) was >0.90.
(vii) The conformations of side chains from the backbone coordinates were predicted. In order to predict the side chain conformations suitable for the protein environment, the extended side chains (except Cp atoms) in the standard helices were first removed from the predicted 3D model. A method that uses a side-chain rotamer library, followed by Monte Carlo optimization (Holm and Sander, 1991) , was used to grow the side chains back using the backbone coordinates. The result of this strategy is that close contact between side chains was eliminated.
(viii) The model was refined with energy minimization. The predicted 3D model was refined by energy minimization, using the CHARMM forcefield, with 500 cycles of steepest-descent minimization followed by 1000 cycles of conjugate gradient minimization.
Identification of a candidate ligand binding site
One of the main limitations of the procedure used to construct the model of the ligand free receptor is that it does not explicitly incorporate helix tilt and uses ideal helix geometry to construct an initial 3D model of the helix bundle. The detailed placement of the ligand in the binding pocket can be affected by these limitations. In addition, since the opioid receptor sequences have only recently been determined, the number of point mutations made to obtain knowledge of important amino acids that interact with the ligands is small (Kong and Reisine, 1993; Surratt etal, 1994) . Thus, as an initial assessment of the validity of the optimized model, a candidate binding site using four structurally diverse, high 5 affinity ligands was identified and the extent to which it contained many residues in positions known to affect ligand binding in other GPCRs was determined. In this study, the four structurally disparate, high affinity 8 opioid receptor ligands shown in Figure 2 , with affinities given in Table I , were used to identify a plausible binding site. These are the fused ring naltrindole and the tetrapeptide TTPPNH2 (Tyr-Tic-Phe-Phe-NHx) (both antagonists) and two agonists, lofentanil and BW373U86. To identify a plausible ligand binding site, the protonated amine, common to all opioids, was tethered to the conserved Asp 127 in TM helix 3. This assumption was made based on mutation data (Surratt etal, 1994) that allowed the deduction that the protonated amino in opioids, a feature common to all neurotransmitter receptor ligands, should be close to and pointing in the direction of the conserved Asp 127 in the third TM helix. Mutation of this conserved aspartic acid has also been shown to diminish ligand binding in other receptor systems, for example in [J-adrenergic receptors (Strader etal., 1989a; Strader and Dixon, 1991) . Another aspartic acid present in the second TM helix is thought to be involved in agonist and antagonist recognition and activation. However, recently it has been shown that its probable function is an ionic interaction with a conserved asparagine present in TM7 (Sealfon etal., 1995) , rather than direct interaction with the ligand. In addition to the proximity of the protonated amine to the Asp 127, in the search for the binding site, the knowledge that no known mutants of residues in TM1 affected binding was used as an additional constraint.
With this limited use of known mutation data, a systematic search was made for a binding site that could accommodate the four structurally diverse ligands in an orientation to interact with receptor residues complementary to the ligand moieties previously postulated as requirements for recognition of the 8 opioid receptor (Chew etai, 1993; Maguire and Loew, 1993; Agarwal etal., 1995; Chao etai, 1995) . Specifically, as indicated in the schematic structures in Figure 2 , these deter-580 minants were a protonated amine nitrogen labeled D, an aromatic ring labeled A and one of two lipophilic moieties labeled B and C. The additional polar entities labeled E and F, while present in some analogs, are absent in other compounds used to develop a 3D recognition pharmacophore for the 8 opioid receptor (Agarwal etai, 1995) and are not required for recognition. Energy minimization of each initial ligandreceptor complex was performed using the CHARMM forcefield, with 500 cycles of steepest-decent minimization followed by 1000 cycles of conjugate gradient minimization.
Results and discussion
3D Model of the 8 opioid receptor
The evolutionary tree of the 42 sequences used in the construction of the model receptor is shown in Figure 3 . It can be seen that the opioid receptors share >50% identity with each other and are >30% identical with the somatostatin receptor family and >20% identical with the angiotensin receptor family. As shown in Figure 4 , the variability profile of the peptide receptors clearly indicates seven regions with V(J) s= 0.0 which can be identified as TM regions. The boundaries of these TM regions in alignment positions as well as in residue numbers of mouse 8 opioid receptor are shown in Table n. The predicted TM regions for all the sequences studied are gathered in Table HI .
The values obtained for the alpha periodicity index, AP, for these predicted TM regions are also shown in Table II . Almost all the TM regions have AP values close to 2.0 or higher, indicating a-helical secondary structures (Komiya etal, 1988) . Although the AP values of TM helices 3 and 7 are <2.0, a helical conformation can be assumed for these regions based on their comparable length with other TM regions. Similar disparities were found in the case of the modeling of BR and opsins, but not in the neurotransmitter receptors for which the number of sequences was larger, illustrating the sensitivity of this parameter to the total number of sequences studied. In general, as shown in Figure 5 , a maximum value near 100° can be found, indicating a helical conformation of these regions.
Of the two possible models of helix packing, clockwise and counterclockwise when observed from the intercellular side, only the clockwise model was built, since in other GPCR models (Maloney-Huss and Lybrand, 1992; Baldwin, 1993; Alkorta and Du, 1994) it has been shown to be the more plausible. The disposition of the helices in the 3D model obtained and their corresponding variability moments are shown in Figure 6 . The correlation coefficient obtained between <A> and <V> in this model was 0.93. As shown in this figure, the variability moments of all the helices point towards the lipid phase, tending to validate this model. The general shape of the model shown in Figure 6 is similar to that of the low resolution rhodopsin structure (Baldwin, 1993; Schertler etal, 1993) in that the TM helices 3 and 7 are the most buried in the bundle while helices 1 and 4 are most exposed to the lipid phase. Also, as shown in this figure, the side chains of the residues in the 8 opioid receptor in equivalent positions to all residues that have been shown by mutation studies of any GPCR to modulate ligand binding are inside the helix bundle.
Assessment of model by characterization of ligand binding site
Given the sparsity of published point mutation data for the opioid receptors, continued use of the many residues in positions known to affect ligand binding in other GPCRs can be made to assess the validity of the candidate binding site identified in the optimized ligand-receptor complexes. Since this binding site was identified primarily by using the requirements for ligand recognition deduced from the properties of the ligands themselves, the extent to which it contains these residues is another validation of this model. Figures 7-10 show the optimized complex of each of the four ligands in the candidate binding site of the mouse 8 opioid receptor. Table IV lists the amino acids in each TM helix within 5 A of any atom of each ligand. In this table we have also indicated specific residues that interact with the ligand recognition moieties deduced previously to be modulators of recognition of this receptor. From these figures and this table, it can be seen that all four ligands that include agonists and antagonists as well as peptide and non-peptide analogs bind in the same general region of the receptor. In addition, this binding site can accommodate each of these structurally disparate ligands in such a way that the postulated common recognition interactions are preserved. These explicit ligandreceptor complexes obtained for the first time for the 8 opioid receptor provide additional insights of how disparate ligands, agonists and antagonists, peptides and non-peptides can all satisfy similar requirements for recognition by small variations in their mode of binding to similar regions of the receptor.
Although the 3D model of the 8 opioid receptor and the candidate binding site identified here appears to be consistent with the pharmacophore deduced by studies of the ligands alone, as stated, experimental studies of the effect of point mutations on ligand recognition and activation are needed to assess further, validate and refine this model. At present, because of the relatively recent cloning and sequencing of this receptor, very few point mutations of it have been reported. Studies of results from chimeric receptors composed of fragments of different opioid receptors (Wang etal., 1994) , while interesting, cannot be directly used to assess this binding site. There are, however, a large number of known mutations for other GPCRs which can be used for initial assessment of the current model. To this end, in Table V we have compared the residues predicted to be within 5 A of each ligand (Table IV) with the residues in the 8 opioid receptor in equivalent positions to all residues that have been shown by mutation studies of any GPCR to modulate ligand binding. Comparing Tables IV  and V , it can be seen that many of the residues found to modulate binding in a GPCR form part of our proposed binding site. Since most of this information was not used to identify the binding site, the consistency obtained serves as an initial validation of it.
This model can also serve as a guide for further studies of mutations of the 8 opioid receptor itself. The results of such mutation studies can then in turn be used to assess and refine the model further. This iterative process involving structurebased selection of candidates for mutation and refinement of model structures using these results should ultimately lead to a 3D model reliable enough to provide mechanistic insight into ligand recognition and activation of this receptor, and the design of novel 8-selective ligands.
